{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-25-000040","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2025-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.606986+00:00","generated_at":"2026-05-17T01:55:29.606998+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Akebia abandons Vafseo broad label pursuit for non-dialysis CKD after FDA alignment failure","bullets":["Akebia will not initiate the VALOR trial for vadadustat in late-stage CKD not on dialysis after FDA feedback.","FDA indicated the trial would require significantly more patients and meaningfully more time and cost.","Akebia does not expect to pursue a broad label for Vafseo for non-dialysis dependent CKD patients.","Vafseo remains approved only for anemia in dialysis-dependent CKD patients; launched in U.S. Jan 2025.","Akebia is encouraged by FDA discussion on smaller subgroups but no specific path forward yet."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-25-000040","json":"https://secwatch.observer/filing/0001517022-25-000040.json","markdown":"https://secwatch.observer/filing/0001517022-25-000040.md","text":"https://secwatch.observer/filing/0001517022-25-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000040/0001517022-25-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000040/akba-20251028.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:55:29.606998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}